Andrea Dunaif1. 1. Division of Endocrinology, Metabolism, and Molecular Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611.
Abstract
CONTEXT: Polycystic ovary syndrome (PCOS) is a common complex genetic disease. It is characterized by hyperandrogenism, gonadotropin secretory changes, polycystic ovarian morphology, and insulin resistance. The etiology of PCOS remains unknown, but modern genetic approaches, such as genome-wide association studies (GWAS), Mendelian randomization, and next-generation sequencing, promise to identify the pathways that are primarily disrupted. EVIDENCE ACQUISITION: The literature on PCOS, including the author's research, is discussed. EVIDENCE SYNTHESIS: Recent genetic analyses are reviewed. CONCLUSIONS: Considerable progress has been made mapping PCOS susceptibility genes. GWAS have implicated gonadotropin secretion and action as important primary defects in disease pathogenesis in European and Han Chinese PCOS cohorts, respectively. European women with the National Institutes of Health and Rotterdam phenotypes as well as those with self-reported PCOS have some gene regions in common, such as chromosome 11p14.1 region containing the FSH B polypeptide (FSHB) gene, suggesting shared genetic susceptibility. Several chromosomal signals are significant in both Han Chinese and European PCOS cohorts, suggesting that the susceptibility genes in these regions are evolutionarily conserved. In addition, GWAS have suggested that DENND1A, epidermal growth factor signaling, and DNA repair pathways play a role in PCOS pathogenesis. Only a small amount of the heritability of PCOS is accounted for by the common susceptibility variants mapped so far. Future studies should clarify the contribution of rare genetic variants and epigenetic factors to the PCOS phenotype. Furthermore, Mendelian randomization can be used to clarify causal relationships, and phenome-wide association studies can provide insight into health risks associated with PCOS susceptibility variants.
CONTEXT: Polycystic ovary syndrome (PCOS) is a common complex genetic disease. It is characterized by hyperandrogenism, gonadotropin secretory changes, polycystic ovarian morphology, and insulin resistance. The etiology of PCOS remains unknown, but modern genetic approaches, such as genome-wide association studies (GWAS), Mendelian randomization, and next-generation sequencing, promise to identify the pathways that are primarily disrupted. EVIDENCE ACQUISITION: The literature on PCOS, including the author's research, is discussed. EVIDENCE SYNTHESIS: Recent genetic analyses are reviewed. CONCLUSIONS: Considerable progress has been made mapping PCOS susceptibility genes. GWAS have implicated gonadotropin secretion and action as important primary defects in disease pathogenesis in European and Han Chinese PCOS cohorts, respectively. European women with the National Institutes of Health and Rotterdam phenotypes as well as those with self-reported PCOS have some gene regions in common, such as chromosome 11p14.1 region containing the FSH B polypeptide (FSHB) gene, suggesting shared genetic susceptibility. Several chromosomal signals are significant in both Han Chinese and European PCOS cohorts, suggesting that the susceptibility genes in these regions are evolutionarily conserved. In addition, GWAS have suggested that DENND1A, epidermal growth factor signaling, and DNA repair pathways play a role in PCOS pathogenesis. Only a small amount of the heritability of PCOS is accounted for by the common susceptibility variants mapped so far. Future studies should clarify the contribution of rare genetic variants and epigenetic factors to the PCOS phenotype. Furthermore, Mendelian randomization can be used to clarify causal relationships, and phenome-wide association studies can provide insight into health risks associated with PCOS susceptibility variants.
Authors: Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh Journal: J Lipid Res Date: 2012-07-17 Impact factor: 5.922
Authors: T M Barber; A J Bennett; C J Groves; U Sovio; A Ruokonen; H Martikainen; A Pouta; A-L Hartikainen; P Elliott; C M Lindgren; R M Freathy; K Koch; W H Ouwehand; F Karpe; G S Conway; J A H Wass; M-R Järvelin; S Franks; M I McCarthy Journal: Diabetologia Date: 2008-05-14 Impact factor: 10.122
Authors: Lourdes Ibáñez; Abel López-Bermejo; Marta Díaz; Maria Victoria Marcos; Francis de Zegher Journal: J Clin Endocrinol Metab Date: 2008-03-04 Impact factor: 5.958
Authors: Stephen Franks; Lisa J Webber; Micaela Goh; Anne Valentine; Davinia M White; Gerard S Conway; Steven Wiltshire; Mark I McCarthy Journal: J Clin Endocrinol Metab Date: 2008-06-17 Impact factor: 5.958
Authors: Hashem A Shihab; Julian Gough; David N Cooper; Peter D Stenson; Gary L A Barker; Keith J Edwards; Ian N M Day; Tom R Gaunt Journal: Hum Mutat Date: 2012-11-02 Impact factor: 4.878
Authors: M Geoffrey Hayes; Margrit Urbanek; David A Ehrmann; Loren L Armstrong; Ji Young Lee; Ryan Sisk; Tugce Karaderi; Thomas M Barber; Mark I McCarthy; Stephen Franks; Cecilia M Lindgren; Corrine K Welt; Evanthia Diamanti-Kandarakis; Dimitrios Panidis; Mark O Goodarzi; Ricardo Azziz; Yi Zhang; Roland G James; Michael Olivier; Ahmed H Kissebah; Elisabet Stener-Victorin; Richard S Legro; Andrea Dunaif Journal: Nat Commun Date: 2015-08-18 Impact factor: 14.919
Authors: E S Barrett; K M Hoeger; S Sathyanarayana; D H Abbott; J B Redmon; R H N Nguyen; S H Swan Journal: J Dev Orig Health Dis Date: 2018-01-09 Impact factor: 2.401
Authors: S V Kellesarian; V R Malignaggi; T V Kellesarian; A A Al-Kheraif; M M Alwageet; H Malmstrom; G E Romanos; F Javed Journal: Int J Impot Res Date: 2017-03-09 Impact factor: 2.896
Authors: Matthew Dapas; Ryan Sisk; Richard S Legro; Margrit Urbanek; Andrea Dunaif; M Geoffrey Hayes Journal: J Clin Endocrinol Metab Date: 2019-04-30 Impact factor: 5.958
Authors: D H Abbott; B H Rayome; D A Dumesic; K C Lewis; A K Edwards; K Wallen; M E Wilson; S E Appt; J E Levine Journal: Hum Reprod Date: 2017-04-01 Impact factor: 6.918